BiotechTube

CABA-201 following preconditioning with fludarabine and cyclophosphamide

Phase 2/3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Inflammatory Myopathy

Conditions

Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis

Trial Timeline

Dec 20, 2023 → Jul 1, 2028

NCT ID
NCT06154252

About CABA-201 following preconditioning with fludarabine and cyclophosphamide

CABA-201 following preconditioning with fludarabine and cyclophosphamide is a phase 2/3 stage product being developed by Cabaletta Bio for Idiopathic Inflammatory Myopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06154252. Target conditions include Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Idiopathic Inflammatory Myopathy were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosinAstraZenecaApproved
✅Omalizumab + PlacebosNovartisApproved
✅Nintedanib + PirfenidoneRocheApproved
✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved
✅TocilizumabRocheApproved

Hype Score Breakdown

Clinical
15
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06154252Phase 2/3Recruiting

Competing Products

20 competing products in Idiopathic Inflammatory Myopathy

See all competitors
ProductCompanyStageHype Score
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Rituximab + cyclosporineSun PharmaceuticalPhase 3
32
E5501EisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
PerampanelEisaiPre-clinical
26
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
35